<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438577</url>
  </required_header>
  <id_info>
    <org_study_id>ShantouCH</org_study_id>
    <nct_id>NCT04438577</nct_id>
  </id_info>
  <brief_title>Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery</brief_title>
  <acronym>LI-CTD</acronym>
  <official_title>Evaluation of the Feasibility and Efficacy of Lidocaine Mucilage-ICG as an Optical Agent to Detect Cancer Tissue Delineation During Breast-conserving Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shantou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shantou Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Around 15%-30% of patients receiving breast-conserving surgery (BCS) for invasive breast&#xD;
      carcinoma or ductal carcinoma in situ (DCIS) need a reoperation due to tumor-positive margins&#xD;
      at final histopathology. Currently available modalities used for intraoperative surgical&#xD;
      margin assessment all have specific limitations. In order to improve intraoperative tumor&#xD;
      localization and surgical margin assessment in BCS, we developed a fluorescent tracer, the&#xD;
      Lidocaine mucilage-ICG tracer, which could be locally injected and detected by fluorescent&#xD;
      camera systems during operation. In this study, we aim to evaluate the efficacy of Lidocaine&#xD;
      mucilage-ICG as an agent for intraoperative tumor delineation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Margin width</measure>
    <time_frame>7 days</time_frame>
    <description>The distance between tumor and margin on the gross specimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive margin rate</measure>
    <time_frame>7 days</time_frame>
    <description>The percentage of patients with a positive margin out of the participants</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Efficacy of Lidocaine mucilage-ICG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efficacy of Lidocaine mucilage-ICG for intraoperative tumor delineation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine mucilage-ICG</intervention_name>
    <description>Lidocaine mucilage-ICG as an agent for intraoperative tumor delineation</description>
    <arm_group_label>Efficacy of Lidocaine mucilage-ICG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female at least 18 years old&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast carcinoma&#xD;
&#xD;
          -  Patients planned to receive a breast-conserving surgery&#xD;
&#xD;
          -  Patients received a preoperative breast magnetic resonance imaging&#xD;
&#xD;
          -  Informed consent form understood and signed&#xD;
&#xD;
          -  Patient agrees to all follow-up visits&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group(ECOG) performance status 0 to 1 within 14 days of&#xD;
             study entry&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 7 days prior to the surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric or other condition that may interfere with the study&#xD;
&#xD;
          -  Known allergy or contraindication to any study drug&#xD;
&#xD;
          -  Patients received neoadjuvant therapies&#xD;
&#xD;
          -  Patients received an excision biopsy of the tumor&#xD;
&#xD;
          -  Breast feeding period&#xD;
&#xD;
          -  Pregnant (female of childbearing potential only)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Si-Qi Qiu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shantou Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mian-Han Zhuang</last_name>
    <phone>008613750445342</phone>
    <email>jgbst@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shantou Central Hospital</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Si-Qi Qiu, Dr.</last_name>
      <phone>008613790868950</phone>
      <email>s_patrick@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shantou Central Hospital</investigator_affiliation>
    <investigator_full_name>Si-Qi Qiu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast conserving surgery; fluorescence-guided surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

